Related Experiment Video
Updated: Jan 25, 2026

Driving Under the Influence: How Music Listening Affects Driving Behaviors
Published on: March 27, 2019
RUNX represses Pmp22 to drive neurofibromagenesis
Ashley Hall1, Kwangmin Choi1, Wei Liu1
1Cincinnati Children's Hospital Medical Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, University of Cincinnati, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
Abstract:
Patients with neurofibromatosis type 1 (NF1) are predisposed to develop neurofibromas, but the underlying molecular mechanisms of neurofibromagenesis are not fully understood. We showed dual genetic deletion of Runx1 and Runx3 in Schwann cells (SCs) and SC precursors delayed neurofibromagenesis and prolonged mouse survival. We identified peripheral myelin protein 22 (Pmp22/Gas3) related to neurofibroma initiation. Knockdown of Pmp22 with short hairpin RNAs increased Runx1 tumor-derived sphere numbers and enabled significantly more neurofibroma-like microlesions on transplantation. Conversely, overexpression of Pmp22 in mouse neurofibroma SCs decreased cell proliferation. Mechanistically, RUNX1/3 regulated alternative promoter usage and induced levels of protein expression of Pmp22 to control SC growth. Last, pharmacological inhibition of RUNX/core-binding factor β (CBFB) activity significantly reduced neurofibroma volume in vivo. Thus, we identified a signaling pathway involving RUNX1/3 suppression of Pmp22 in neurofibroma initiation and/or maintenance. Targeting disruption of RUNX/CBFB interaction might provide a novel therapy for patients with neurofibroma.
Insights
Neurofibromatosis type 1 (NF1) patients develop neurofibromas. RUNX1/3 suppression of Pmp22 in Schwann cells drives neurofibroma initiation. Targeting RUNX/CBFB interaction may offer new NF1 therapies.
Area of Science:
- Oncology
- Genetics
- Cell Biology
Background:
- Neurofibromatosis type 1 (NF1) patients are prone to developing neurofibromas.
- The molecular mechanisms driving neurofibroma development remain unclear.
- Schwann cells (SCs) and their precursors are implicated in neurofibromagenesis.
Purpose of the Study:
- To investigate the role of RUNX1 and RUNX3 in neurofibroma development.
- To identify molecular targets for potential NF1 therapies.
Main Methods:
- Dual genetic deletion of Runx1 and Runx3 in mouse SCs and SC precursors.
- Investigating the role of peripheral myelin protein 22 (Pmp22) in neurofibroma initiation.
- Using short hairpin RNAs for Pmp22 knockdown and Pmp22 overexpression in SCs.
- Assessing neurofibroma-like microlesions and tumor-derived sphere numbers.
- Pharmacological inhibition of RUNX/core-binding factor beta (CBFB) activity.
Main Results:
- Dual deletion of Runx1 and Runx3 delayed neurofibroma formation and improved mouse survival.
- Pmp22 was identified as a key factor in neurofibroma initiation.
- Pmp22 knockdown increased tumor sphere numbers and neurofibroma-like lesions.
- Pmp22 overexpression reduced SC proliferation.
- RUNX1/3 regulate Pmp22 expression to control SC growth.
- Pharmacological inhibition of RUNX/CBFB significantly reduced tumor volume.
Conclusions:
- A signaling pathway involving RUNX1/3 suppression of Pmp22 is crucial for neurofibroma initiation and maintenance.
- Targeting the RUNX/CBFB interaction presents a potential therapeutic strategy for NF1 patients.
Related Concept Videos
Repressed Memory
Repressible Operon: trp Operon
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Drive-Reduction Theory: Push Theory of Motivation
Euchromatin
Euchromatin is the less dense region of the chromatin and stains lighter. Euchromatin contains histone H3 extensively...

